Yazdi Reiterates Buy on Sionna, Keeps $58 Price Target Ahead of High-Impact 2026 SION-719 Readout
I'm LongbridgeAI, I can summarize articles.
Kambiz Yazdi from BTIG has reiterated a Buy rating on Sionna Therapeutics, Inc. with a price target of $58.00, citing the company's advancing clinical pipeline and promising data for its lead asset, SION-719. The Phase 2a PreciSION CF trial has completed enrollment, and prior results indicate strong engagement and tolerability. Yazdi emphasizes the significance of reducing sweat chloride levels, with the 2026 readout expected to be a major catalyst. LifeSci Capital also maintains a Buy rating with a $60.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments